Organogenesis Holdings Inc (ORGO) is a regenerative medicine company that develops and markets products for the advanced wound care and surgical and sports medicine markets. The company's products include wound care, surgical, and sports medicine products, as well as bio-active tissue matrices and allografts. Organogenesis also provides contract manufacturing services to third-party customers.
The company's advanced wound care products include Apligraf and Dermagraft, which are bio-engineered skin substitutes used to treat chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The surgical and sports medicine products include PuraPly and PuraPly Antimicrobial, which are used for soft tissue reinforcement and wound protection in surgical procedures.
Organogenesis was founded in 1985 and is headquartered in Canton, Massachusetts. The company is traded on the Nasdaq Global Select Market under the ticker symbol ORGO.
Organogenesis Holdings Inc (ORGO) is a regenerative medicine company that develops and markets products for the advanced wound care and surgical and sports medicine markets. The company's products include wound care, surgical, and sports medicine products, as well as bio-active tissue matrices and allografts. Organogenesis also provides contract manufacturing services to third-party customers.